医学
药代动力学
治疗药物监测
加药
抗菌剂
造血干细胞移植
抗生素
药理学
药品
重症监护医学
造血干细胞
治疗指标
肿瘤科
分配量
移植
相伴的
内科学
干细胞
造血
分布(数学)
血浆浓度
化疗
多药
作者
Parisa Ghasemiyeh,Elahehnaz Parhizkar,Soliman Mohammadi‐Samani
标识
DOI:10.1080/14787210.2026.2706021
摘要
INTRODUCTION: Hematopoietic stem cell transplantation (HSCT) is considered the treatment of choice for various malignant and nonmalignant hematologic disorders. HSCT patients are commonly subject to polypharmacy and receive multiple therapeutic regimens during the pre-, peri-, and post-transplantation periods. Administration of various antimicrobial agents as prophylactic or therapeutic regimens is essential in HSCT patients. AREAS COVERED: This comprehensive review focuses mainly on the pharmacokinetic (PK) aspects and therapeutic drug monitoring (TDM) of commonly administered antimicrobial agents, including antibacterial, antiviral, and antifungal agents in HSCT patients. Additionally, alterations in PK parameters and specific recommendations for TDM are discussed in detail. EXPERT OPINION: Since HSCT patients often have altered PK characteristics and require multiple concomitant medications, individualized dosing based on their PK and pharmacogenetic profiles is crucial. Close monitoring of potential drug-drug interactions (PDDIs) and plasma concentrations is essential to achieve an optimal clinical response, minimize drug-related toxicities, and improve post-transplant survival. In general, many of the commonly administered antibiotics in HSCT patients showed increased volume of distribution and clearance, decreased half-lives, and therefore decreased area under the curve (AUC) values compared to the normal population. Therefore, higher doses of these antibiotics should be administered along with close patient monitoring and assessment of plasma concentrations.
科研通智能强力驱动
Strongly Powered by AbleSci AI